Thousand Oaks, California
United States
41
2025-12-11
35
2025-07-29
These are the the leading inventors for applications assigned to CHEMOCENTRYX, INC.:
CHEMOCENTRYX, INC. based in Thousand Oaks, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
CAPSULE FORMULATIONS
#2 | 2025-11-13HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES
#3 | 2025-03-20METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES
#4 | 2025-03-20CXCR7 INHIBITORS FOR THE TREATMENT OF CANCER
#5 | 2024-08-29COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
#6 | 2024-04-25 ā Patent 12,371,433 granted on 2025-07-29HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES
#7 | 2024-03-28COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES
#8 | 2023-10-12 ā Patent 12,497,383 granted on 2025-12-16HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES
#9 | 2023-05-18 ā Patent 11,773,091 granted on 2023-10-036-5 fused rings as C5a inhibitors
#10 | 2023-04-27 ā Patent 12,012,403 granted on 2024-06-18Aryl sulfonyl compounds as CCR6 inhibitors
#11 | 2023-04-20 ā Patent 12,139,475 granted on 2024-11-122-oxindole compounds
#12 | 2023-04-20 ā Patent 11,793,771 granted on 2023-10-24Immunomodulator compounds
#13 | 2023-04-13 ā Patent 12,268,675 granted on 2025-04-08Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
#14 | 2023-03-30 ā Patent 12,011,439 granted on 2024-06-18Combination therapy using CāC chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
#15 | 2023-02-09 ā Patent 12,533,354 granted on 2026-01-27TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES
#16 | 2023-01-26 ā Patent 12,611,409 granted on 2026-04-28COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
#17 | 2023-01-12 ā Patent 11,845,729 granted on 2023-12-19PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
#18 | 2022-11-10 ā Patent 11,779,576 granted on 2023-10-10Method of treating C3 glomerulopathy
#19 | 2022-09-22 ā Patent 12,350,263 granted on 2025-07-08DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
#20 | 2022-09-08 ā Patent 11,684,606 granted on 2023-06-27Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
#21 | 2022-07-28 ā Patent 11,951,214 granted on 2024-04-09Capsule formulations
#22 | 2022-07-21 ā Patent 12,194,032 granted on 2025-01-14Method of treating focal segmental glomerulosclerosis
#23 | 2022-06-23 ā Patent 11,884,654 granted on 2024-01-30Substituted anilines as CCR(4) antagonists
#24 | 2022-06-09 ā Patent 11,759,458 granted on 2023-09-19Indane-amines as PD-L1 antagonists
#25 | 2022-05-19 ā Patent 12,054,484 granted on 2024-08-06Substituted tetrahydropyrans as CCR2 modulators
#26 | 2022-04-28 ā Patent 11,834,452 granted on 2023-12-05CXCR7 antagonists
#27 | 2022-04-28 ā Patent 11,844,790 granted on 2023-12-19Methods of treating hidradenitis suppurativa
#28 | 2022-04-21 ā Patent 11,691,985 granted on 2023-07-04Macrocyclic immunomodulators
#29 | 2022-02-17 ā Patent 12,611,404 granted on 2026-04-28AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES
#30 | 2022-01-13 ā Patent 11,820,759 granted on 2023-11-21Modulators of chemokine receptors
#31 | 2022-01-13 ā Patent 11,945,805 granted on 2024-04-02Inhibitors of CXCR2
#32 | 2021-12-30 ā Patent 11,890,276 granted on 2024-02-06Methods of treating pancreatic cancer
#33 | 2021-11-11 ā Patent 11,986,466 granted on 2024-05-21Methods of treating solid tumors with CCR2 antagonists
#34 | 2021-10-07 ā Patent 11,883,391 granted on 2024-01-30Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
#35 | 2021-09-09 ā Patent 11,807,609 granted on 2023-11-07Deuterated compounds as immunomodulators
#36 | 2021-05-20 ā Patent 11,708,326 granted on 2023-07-25Immunomodulator compounds
#37 | 2021-05-06 ā Patent 11,866,429 granted on 2024-01-09Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
#38 | 2021-05-06 ā Patent 11,713,307 granted on 2023-08-01Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
#39 | 2021-04-01 ā Patent 11,759,454 granted on 2023-09-19Diazole lactams
#40 | 2021-01-14 ā Patent 11,872,217 granted on 2024-01-16Indanes as PD-L1 inhibitors
#41 | 2020-09-17 ā Patent 11,744,822 granted on 2023-09-05Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
Also check out CHEMOCENTRYX, INC.'s (Thousand Oaks, United States) applicant profile with 10 patent applications submitted.
349953 ā